Macula Society
Imaging Cases for 2010

Wednesday, February 24, 2010
Imaging and Case Study Conference

4:30 - 6:30 p.m.  Chair: Larry Yannuzzi
                  Moderator: Carol Shields

4:30 p.m.  Philip Rosenfeld
           A Pitiful Outcome

4:36 p.m.  Rajendra Apte
           Sickle Cell Retinopathy with Tangential Traction and a Full
           Thickness Macular Hole

4:42 p.m.  Hyoung Koh
           Prognostic Factors for Visual Outcome after Intravitreal Anti-
           VEGF for Myopic Choroidal Neovascularization

4:48 p.m.  James Folk
           Relapsing Choroiditis

4:54 p.m.  Carol Shields
           Unusual Cause of Macular Edema

5:00 p.m.  Charles Barr
           Unknown or Masquerade Syndrome

5:06 p.m.  Leonidas Zografos
           Wide Field (150°) ICG and Fluorescein Angiography in Uveal
           Melanomas

5:12 p.m.  Michael Marmor
           Youngster Referred for Chronic Serous Detachment

5:18 p.m.  Andrew Lottery
           Successful Treatment of Choroidal Neovascularization
           Secondary to Sorsby's Fundus Dystrophy with Intravitreal
           Bevacizumab

5:24 p.m.  Mark Johnson
           Mystery Case

-20-
5:30 p.m.  Stephen Tsang  
Autofluorescence Imaging and Phenotypic Variance in a Sibling Pair with Early Onset Retinal Dystrophy Due to Defective CRB1 Function

5:36 p.m.  Salomon Cohen  
West-Indies Crackled Retinal Pigment Epitheliopathy

5:42 p.m.  K. Frendel  
Using the SD-OCT “Time Machine” to Clarify the Origin of Type 3 Neovascularization

5:48 p.m.  Mathew MacCumber  
Vitrectomy for Myopic Macular Retinoschisis

5:54 p.m.  Anita Agarwal  
Salt and Pepper Fundus in Women in a Family

6:00 p.m.  Robert Liss  
Choroidal Neovascularization in a Child, unknown. Long-Term Follow Up

6:06 p.m.  Michaella Goldstein  
Macular Edema?

6:12 p.m.  Lawrence Yannuzzi  
A Mystery Curvilinear Tract in the Fundus: Straightening it Out

6:18 p.m.  Richard Spaide  
Fluorescein Case — Panretinal Fluorescein Angiogram of Central Retinal Vein Occlusion

6:24 p.m.  Jose Pulido  
Effect of PDT on Peripapillary Lesion
2010
Scientific Program

Thursday, Friday and Saturday

February 25 – 27, 2010
Tucson, Arizona

The eight minutes allotted time for each presentation includes 6 minutes presentation and 2 minutes of time for discussion and audience polling
THURSDAY, FEBRUARY 25, 2010

SESSION I
Diabetes I

7:25 a.m.  Introduction and dedication to W. Richard Green
Jerry Shields

Chair: Susan Bressler  Moderator: Lloyd Aiello

7:30 a.m.  Comparison of Film and Digital Fundus Photographs in Diabetic Retinopathy
Michael Ip

7:38 a.m.  Decreased SHP-1 Expression Correlates with Protection from Diabetic Retinopathy Despite Poor Glycemic Control and Extreme Duration Diabetes
Lloyd Aiello

7:46 a.m.  Ischemic Diabetic Retinopathy Protects against Nuclear Sclerotic Cataract
Nancy Holekamp

7:54 a.m.  Observational Study of Subclinical Diabetic Macular Edema
Susan Bressler

8:02 a.m.  Pooled Analysis of the Relationship of OCT-Measured Central Retinal Thickness with Visual Acuity and Level of Diabetic Retinopathy in DRCR Network Studies
Michael Elman

8:10 a.m.  Impact of Antiangiogenic Therapy on Intraretinal Exudates in Diabetic Macular Edema (DME)
Ursula Schmidt-Erfurth

8:18 a.m.  Fluocinolone Acetonide Intravitreal Insert (Iluvien®) for Diabetic Macular Edema—Results of the Phase 3 Randomized Controlled Trial
David Brown

8:26 a.m.  Triple Therapy (Combined Subtenon Triamcinolone, Intravitreal Bevacizumab and Laser Photocoagulation) for Refractory Diabetic Macular Edema: One-Year Results
Dennis Lam

8:34 a.m.  Open-Label Phase 2 Study of Dexamethasone Intravitreal Implant for Treatment of Diabetic Macular Edema (DME) in Vitrectomized Patients: Interim Results
David Boyer

8:42 a.m.  Discussion
### SESSION II
#### AMD I

**Chair:** Johanna Seddon  
**Moderator:** Jason Slakter

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:47 a.m.</td>
<td>Prediction Models and New Genetic Pathways for Age-Related Macular Degeneration</td>
<td>Johanna Seddon</td>
</tr>
<tr>
<td>8:55 a.m.</td>
<td>Computational Discovery of Genetically Controlled AMD Phenotypes</td>
<td>Michael Abramoff</td>
</tr>
<tr>
<td>9:03 a.m.</td>
<td>Influence of Genotype on Clinical Features of AMD</td>
<td>Gisele Soubrane</td>
</tr>
<tr>
<td>9:11 a.m.</td>
<td>Effect Modifiers of Progression to Advanced AMD Using the Age-Related Eye Disease Study (AREDS) Simple Scale</td>
<td>Emily Chew</td>
</tr>
<tr>
<td>9:19 a.m.</td>
<td>Effect of Pattern of Geographic Atrophy from AMD on Enlargement Rate</td>
<td>Janet Sunness</td>
</tr>
<tr>
<td>9:27 a.m.</td>
<td>Prevalence and Significance of Subretinal Drusenoid Deposits (Reticular Pseudodrusen) in Age-Related Macular Degeneration</td>
<td>Richard Spaide</td>
</tr>
<tr>
<td>9:35 a.m.</td>
<td>Not all Drusen are Created Equal</td>
<td>Anita Agarwal</td>
</tr>
<tr>
<td>9:43 a.m.</td>
<td>A Novel SD-OCT Algorithm for the Quantification of Drusen Area and Volume</td>
<td>Philip Rosenfeld</td>
</tr>
<tr>
<td>9:51 a.m.</td>
<td>Biomarkers and New Therapeutic Approaches in Age-Related Macular Degeneration</td>
<td>Jason Slakter</td>
</tr>
<tr>
<td>9:59 a.m.</td>
<td>The Complement System in AMD: Pathogenic Insights and the Rationale for Anti-Factor D in Geographic Atrophy</td>
<td>Dante Pieramici</td>
</tr>
<tr>
<td>10:07 a.m.</td>
<td>Targeting Complement Factor 5 in Geographic Atrophy in Dry Age-Related Macular Degeneration – A Phase 1 Study</td>
<td>Jordi Mones</td>
</tr>
<tr>
<td>10:15 a.m.</td>
<td>Effects of Vitrectomy on Age-Related Macular Degeneration</td>
<td>James Folk</td>
</tr>
<tr>
<td>10:23 a.m.</td>
<td>Break</td>
<td></td>
</tr>
</tbody>
</table>
SESSION III
AMD II

Chair: Thomas Ciulla
Moderator: Barry Kuppermann

10:40 a.m. Patient-Reported Outcomes from Sham vs. No-Treatment Controls from Randomized Trials
Barbara Hawkins

10:48 a.m. Associations between Aspirin Use and AMD
Paulus de Jong

10:56 a.m. Retinal “Scavenger” Cysts in Anti-VEGF Treated Exudative Age-Related Macular Degeneration: A Spectral Domain OCT Study
Martine Mauget-Fayssse

11:04 a.m. Intraocular Pressure in Eyes Receiving Monthly Ranibizumab: Analysis of Data from the MARINA and ANCHOR Trials
Sophie Bakri

11:12 a.m. Ranibizumab (Lucentis®) for Neovascular Age-Related Macular Degeneration (AMD): 2-Year Results for Fellow Eyes with Neovascular AMD in MARINA and ANCHOR Trials
Thomas Ciulla

11:20 a.m. Ranibizumab Treatment of Phakic vs. Pseudophakic Eyes with Macular Degeneration: A Meta-Analysis of 2 Pivotal Trials
David Weinberg

11:28 a.m. Visual and Anatomic Outcomes of Intravitreal Anti-VEGF Therapy for Exudative Age-Related Macular Degeneration with Significant Epiretinal Membrane
Natsumi Chaudhry

11:36 a.m. Inject and Extend vs. PRN: A Comparative Retrospective Study of Ranibizumab in Exudative Age-Related Macular Degeneration
Salomon Cohen

11:44 a.m. Visual Acuity Loss Associated with Extended Dosing Regimens of Ranibizumab and Bevacizumab for Neovascular Macular Degeneration
John Thompson

11:52 a.m. Safety and Efficacy of OZURDEX (Dexamethasone Intravitreal Implant) as Adjunctive Therapy to Lucentis® in Patients with Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)
Baruch Kuppermann

12:00 p.m. Discussion

-26-
12:05 p.m.  **Presentation of the Arnall Patz Medal Award**  
*Recipient: Lawrence A. Yannuzzi, MD*  
*Presenter: Kurt A. Gitter, MD, MD*

12:13 p.m.  **Paul Henkind Memorial Lecture and Award Presentation**  
*Recipient: Anthony P. Adams, MD*  
*Presenter: Evangelos S. Gragoudas, MD*

12:37 p.m.  **Session Ends**

---

**FRIDAY, FEBRUARY 26, 2010**

**Business Meeting**

7:00 a.m.  *Macula Society Members Only*

**SESSION IV**  
**Basic Science, Degenerations, and Stem Cells**

*Chair: Jose Pulido*  
*Moderator: Andrew Lotery*

7:30 a.m.  **Effect of HDAC Inhibitors on Retinal Cells**  
*Shalesh Kaushal*

7:38 a.m.  **Lentiviral PDE6β Combined with shRNA-Mediated Targeting of Cyclic Nucleotide Gated Channel Alpha 1 Results in an Increase of Photoreceptor Survival in a cGMP Phosphodiesterase Mouse Mutant Model of Retinitis Pigmentosa**  
*Stephen Tsang*

7:46 a.m.  **Generation of Light-Sensitive Photoreceptor Phenotypes by Genetic Modification of Human Adult Ocular Stem Cells Using CRX**  
*Andrew Lotery*

7:54 a.m.  **Estimating the Pathogenic Contribution of Specific ABCA4 Disease Alleles**  
*Edwin Stone*

8:02 a.m.  **A Phase 1 Open-Label, Non-Comparative Study Evaluating the Safety of a Single, Unilateral Subretinal Administration of CNTO2476 (Human umbilical tissue-derived cells [hUTC]) in Advanced Retinitis Pigmentosa (RP)**  
*Peter Francis*

8:10 a.m.  **Novel Mutations and Electrophysiological Findings in RGS9 and R9AP Associated Retinal Dysfunction (“Bradyopsia”)**  
*Graham Holder*
8:18 a.m. A Novel Mutation of LAMB2 Results in Retinal Disease and Diffuse Mesangial Proliferative Glomerulonephritis: A New Variant of Pierson Syndrome  
Jose Pulido

8:26 a.m. Retinal Pathology Linked to Nephropathy in Alport Syndrome  
Paul Bernstein

8:34 a.m. Hydroxychloroquine Toxicity: New Estimates of Risk from a Large National Database  
Michael Marmor

SESSION V
Inflammation/Infections/CSR

Chair: John Heckenlively    Moderator: Emmet Cunningham

8:42 a.m. Neuroimmune Modulatory Gene Profiling of Retinal and RPE Gene Expression after Intravitreal Steroid Injections in Mice  
Lawrence Morse

8:50 a.m. Investigations of Pathologic Mechanisms in Autoimmune Retinopathy  
John Heckenlively

8:58 a.m. The Expanded Clinical Spectrum of Acute Exudative Polymorphous Vitelliform Maculopathy  
Lawrence Yannuzzi

9:06 a.m. Immunosuppression after Fluocinolone Acetonide Implant at a Tertiary Care Center  
James Puklin

9:14 a.m. Prophylactic Anecortave Acetate in Patients with a Retisert Implant  
David Callanan

9:22 a.m. Intravitreal Bevacizumab versus Photodynamic Therapy for the Treatment of Subfoveal Choroidal Neovascularization Secondary to Multifocal Choroiditis  
Francesco Bandello

9:30 a.m. Causes of Vision Loss in a Large Cohort with Ocular Toxoplasmosis  
Emmett Cunningham, Jr.

9:38 a.m. The Incidence of Neonatal Endophthalmitis in the United States May Be Declining  
Andrew Meshgeshi
9:46 a.m. Long-Term Outcome of Half Dose Verteporfin Photodynamic Therapy for the Treatment of Central Serous Chorioretinopathy
Timothy Lai

9:54 a.m. PDT Low-Dose, Low-Fluence Rate for Chronic Central Serous Chorioretinopathy
Francesco Boscia

10:02 a.m. Young Investigator Lecture and Award Presentation
Recipient: Timothy W. Olsen, MD
Presenter: Emily Y. Chew, MD

10:26 a.m. Break

SESSION VI

Tumors

Chair: Evan Gragoudas Moderator: Jerry Shields

10:38 a.m. Hypoxic Modulation Increases Tumor Burden in Retinoblastoma: Evaluation of Periocular Delivery of 2-Deoxy-d-Glucose Alone and as an Adjuvant to Chemotherapy for Treatment of Advanced Retinoblastoma
Timothy Murray

10:46 a.m. Direct Ophthalmic Artery Chemotherapy for RB
David Abramson

10:54 a.m. Enhanced Depth Imaging (OCT) of Choroidal Tumors
Arun Singh

11:02 a.m. Prognosis of Uveal Melanoma in 500 Consecutive Cases Using Genetic Testing of Fine Needle Aspiration Biopsy Specimens
Carol Shields

11:10 a.m. Clinical Outcomes in Patients with Large Uveal Melanomas (Ineligible for the COMS Trial) Treated with Proton Therapy
Evangelos Gragoudas

11:18 a.m. Changing Concepts Regarding Management of Orbital Extension of Uveal Melanoma
Jerry Shields

11:26 a.m. Presentation of the J. Donald M. Gass Medal
Recipient: Alexander J. Brucker, MD
Presenter: Lawrence J. Singerman, MD

11:34 a.m. Presentation of Green Lecture and Award
Recipient: Ralph C. Eagle, Jr., MD
Presenter: Jerry A. Shields, MD
Session VII
Retinal Vascular Diseases

Chair: Neil Bressler  Moderator: Anat Loewenstein

11:58 a.m.  Efficacy and Safety from the BRAVO and CRUISE Trials
            Robert Avery

12:06 p.m.  Vision-Related Patient-Reported Outcomes in BRAVO and CRUISE
            Neil Bressler

12:14 p.m.  12-Month Evaluation of an Applicator-Delivered Dexamethasone Intravitreal Implant in Patients with Macular Edema due to Branch or Central Retinal Vein Occlusion
            Anat Loewenstein

12:22 p.m.  Progress of the MacTel Project
            Mark Gillies

12:30 p.m.  Pharmacokinetic Study of Vitreous and Serum Concentrations of Triamcinolone Acetonide after Posterior Sub-Tenon’s Injection
            Jorge Arroyo

12:38 p.m.  An Alternative Combination Therapy for the Treatment of Congenital Optic Disc Pit Maculopathy
            Shibo Tang

12:46 p.m.  Intravitreal Bevacizumab for Subfoveal Choroidal Neovascularization Associated with Pattern Dystrophy
            Maurizio Parodi

12:54 p.m.  Lamellar Structure of the Vitreous Cortex and Perifoveal Vitreous Detachment in Eyes of Normal Older Individuals
            Shoji Kishi

Session VIII
Ocular Imaging

1:07 p.m.  High Resolution Imaging of the Photoreceptor Layer in the Epiretinal Membrane Using Adaptive Optics Scanning Laser Ophthalmoscopy
            Nagahisa Yoshimura

1:10 p.m.  Subfoveal Choroidal Thickness Following Treatment of Central Serous Chorioretinopathy
            Tomohiro Iida
1:18 p.m.  Resveratrol Regulates Ocular Neovascularization by a Sirt1 Independent and Eukaryotic Elongation Factor-2 Kinase Dependent Pathway  
  *Rajendra Apte*

1:26 p.m.  Session Ends

---

**SATURDAY, FEBRUARY 27, 2010**

**SESSION IX**

**Structure and Imaging**

*Chair: William Mieler*  
*Moderator: Mark Johnson*

8:00 a.m.  Absolute Autofluorescence (AbsAF) Measurements  
  *Theodore Smith*

8:08 a.m.  En Face Visualization and Quantification of Photoreceptor Inner/Outer Segment Junction Using Cirrus Spectral Domain Optical Coherence Tomography and Association with Visual Acuity  
  *William Mieler*

8:16 a.m.  Spectral Domain OCT Imaging of Sickle Cell Anemia Patients  
  *Jennifer Lim*

8:24 a.m.  Adult-Onset Vitelliform Detachment: Correlation of Clinical Findings and Multiple Imaging Analyses  
  *K. Freund*

8:32 a.m.  The Diversity of Traction Mechanisms in Myopic Traction Maculopathy  
  *Mark Johnson*

8:40 a.m.  Clinical and OCT Outcomes of Macular Hole Surgery  
  *Christina Flaxel*

8:48 a.m.  Automated Classification of Bright Lesion Based on Shape: AMD Versus Stargardt's Disease  
  *Stephen Russell*

8:56 a.m.  Decreasing Retinal Photocoagulation Damage: Principles and Technology  
  *Martin Mainster*
Session X
Michaelson Symposium

9:04 a.m.  Introduction
Lawrence J. Singerman, Executive Secretary and
Dr. Daniel P. Michaelson

9:14 a.m.  The Very Basics of VEGF
Eli Kesheit

9:29 a.m.  VEGF in Ophthalmology
Anthony Adamis

9:44 a.m.  Presentation of Inaugural Michaelson Macula Society Recipient
Recipient: Napoleone Ferrara, MD
Presenter: Anthony P. Adamis, MD

9:49 a.m.  Therapeutic Targets for Treating Intraocular Neovascular Diseases, VEGF and Beyond
Napoleone Ferrara

10:19 a.m.  Discussion

Session XI
AMD III

Chair: Marco Zarbin  Moderator: Elias Reichel

10:27 a.m.  Mitogen-Activated Protein Kinase Phosphatase Reduction in AMD
Jayakrishna Ambati

10:35 a.m.  Improved Cell Survival on Aged and AMD Submacular Bruch’s Membrane following Culture in Conditioned Media
Marco Zarbin

10:43 a.m.  Fluorescein Angiographic Findings in PEARL Study of Ranibizumab Therapy for PCV — Importance of ICG Angiography Due to Therapeutic Response Differences between PCV and AMD
Gregg Kakame

10:51 a.m.  The Effects of Intravitreal Anti-VEGF Injections on Ocular Perfusion Pressure
Elias Reichel

10:59 a.m.  Twelve-Month Safety and Visual Acuity Outcome of a Pilot Study Exploring Ranibizumab Combined with Proton Beam Irradiation as Treatment for Exudative Age-Related Macular Degeneration
Susanna Park
11:07 a.m.  Radiation Therapy for Exudative Age-Related Macular Degeneration: Results of a Non-Invasive Approach
Darius Moshfeghi

11:15 a.m.  Regression of Recalcitrant Peripapillary Choroidal Neovascularization after ICG Assisted Oscillating Transpupillary Thermotherapy and Anti-VEGFS
Gholam Peyman

11:23 a.m.  End of Session and Meeting